share_log

UPLOAD: Others

UPLOAD: Others

UPLOAD:其他
美股sec公告 ·  04/16 13:23
Moomoo AI 已提取核心信息
Apollomics Inc., a biopharmaceutical company, has received a comment from the United States Securities and Exchange Commission (SEC) regarding its Registration Statement on Form F-3. The SEC's correspondence, dated April 15, 2024, is a follow-up to Apollomics' response on April 12, 2024, and requests further amendments to the registration statement. The SEC has specifically asked Apollomics to reconcile conflicting information about the residency of its board members. The company had previously indicated that all board members reside outside of China, yet the filing suggests two directors are based in mainland China. The SEC has invited Apollomics to either amend the registration statement or explain why such an amendment is not necessary. The company is expected to respond to the SEC's request, and further comments from the SEC may follow upon review of the amendments and the company's response.
Apollomics Inc., a biopharmaceutical company, has received a comment from the United States Securities and Exchange Commission (SEC) regarding its Registration Statement on Form F-3. The SEC's correspondence, dated April 15, 2024, is a follow-up to Apollomics' response on April 12, 2024, and requests further amendments to the registration statement. The SEC has specifically asked Apollomics to reconcile conflicting information about the residency of its board members. The company had previously indicated that all board members reside outside of China, yet the filing suggests two directors are based in mainland China. The SEC has invited Apollomics to either amend the registration statement or explain why such an amendment is not necessary. The company is expected to respond to the SEC's request, and further comments from the SEC may follow upon review of the amendments and the company's response.
生物制药公司Apollomics Inc. 已收到美国证券交易委员会(SEC)关于其F-3表格注册声明的评论。美国证券交易委员会于2024年4月15日发出的信函是Apollomics于2024年4月12日作出回应的后续信函,并要求对注册声明进行进一步修改。美国证券交易委员会特别要求Apollomics调和有关其董事会成员居住地的相互矛盾的信息。该公司此前曾表示,所有董事会成员都居住在中国境外,但该文件显示有两名董事居住在中国大陆。美国证券交易委员会已邀请Apollomics修改注册声明或解释为什么没有必要进行这样的修改。预计该公司将回应美国证券交易委员会的要求,在审查修正案和公司的回应后,美国证券交易委员会可能会发表进一步的评论。
生物制药公司Apollomics Inc. 已收到美国证券交易委员会(SEC)关于其F-3表格注册声明的评论。美国证券交易委员会于2024年4月15日发出的信函是Apollomics于2024年4月12日作出回应的后续信函,并要求对注册声明进行进一步修改。美国证券交易委员会特别要求Apollomics调和有关其董事会成员居住地的相互矛盾的信息。该公司此前曾表示,所有董事会成员都居住在中国境外,但该文件显示有两名董事居住在中国大陆。美国证券交易委员会已邀请Apollomics修改注册声明或解释为什么没有必要进行这样的修改。预计该公司将回应美国证券交易委员会的要求,在审查修正案和公司的回应后,美国证券交易委员会可能会发表进一步的评论。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息